reported1`S in premenopausal women with systemic lupus erythematosus (SLE), but its pathogenesis is uncertain. 4 Studies on the sequential changes in bone mass in these patients are scarce. 35 Recently, we studied 74 premenopausal women with SLE without any complications or treatment (except for glucocorticoids) that could interfere with bone mineral density. 2 We excluded nine osteoporotic patients according the established World Health Organisation criteria,6 because they were on treatment for low bone density. We repeated the measurement of bone mass after 18 months in 25 consecutive patients, all of whom had continued on glucocorticoid treatment during this period.
Bone mineral density was measured in the lumbar spine (L2-L4) and femoral neck (FN) by dual energy x ray absorptiometry (DXA), using a densitometer (Hologic QDR 1000). Measurement of the bone mineral content, calibrating with the Hologic X-calibre QDR-1 anthropomorphic spine phantom of the known mineral content, was accurate to 0.5%. The precision measurement was better than 0.01 g cm-2 (coefficient of variation = 1.0% at bone mineral density 1.0 g cm-2). Disease activity was assessed with the University College Hospital/Middlesex SLE scoring system,7 by a numerical score graded from 1 to 4 (inactive to severely active disease).
The results were expressed as the mean (SD). For all conventional analyses we used the SPSS/PC software package. A t test was used and the correlations were calculated by linear regression analysis. Results were considered significant at P < 0.05.
At the time of the first densitometry, the mean age was 31.7 (6.8) years, and disease duration was 91 (64) months.
After 18 months there was no significant decrease in bone mineral density, despite glucocorticoid treatment ( The effect ofglucocorticoids on SLE osteoporosis is controversial.' We did not find any correlation between prednisone dose and bone mineral density in chronic steroid users. The effects of glucocorticoids on the bone mass are most pronounced early in the course of steroid treatment.89 These data may partly explain our results. Also, a multifactorial action could explain the lack of correlation between the dose of glucorticoids and bone mineral density. Glucocorticoids may paradoxically inhibit bone resorption that has been stimulated by PGE2 or cytokines.' 01'
In conclusion, after 18 months there were no significant decreases in bone mineral density in premenopausal SLE patients on glucocorticoid treatment. The reported reduction in bone mineral density in these patients may occur at the onset of the disease. Nevertheless, future studies to demonstrate a small loss of bone mineral density in SLE will probably require more patients and a longer period of study. This particular characteristic of Heberden's and Bouchard' s nodes, was pointed out both in hemiplegic subjects following a central cerebral lesion as in the case of Etherington and Spector5-or in upper limbs affected by peripheral paralysis (obstetric paralysis or traumatic interruption of a nerve).
Our case is a 45 year old female who presented with Erb-Duchenne paralysis and Heberden's nodes limited to the healthy side, while the affected arm shows a lack of musculoskeletal development (radius, ulna, carpus, metacarpus, and phalanges) (figure)
In analogy with what has been pointed out in the case of rheumatoid arthritis and hemiplegia67 it is possible formulate several hypotheses: (1) A protective action of central or peripheral neurological lesions with respect to osteoarthritic or arthritic8 manifestations on the affected side, through interruption of the central reflex arc, which is responsible for the symmetric lesions in rheumatoid arthritis and osteoarthrosis. (2) Attenuation of superimposed inflammation in osteoarthrosis by the conditioning of the biochemical expression of the neurogenic inflammation (mediated by substance P, a neuropeptide which acts specifically at low concentrations on "formyl peptide" receptors; this leads to the activation of polymorphonuclear cells and is present both early and in large quantities in inflammed synovium).9 (3) Not be ignored, in our opinion, is the physiological decline of the proprioception in subjects of advancing age'0 and the absence of the normal proprioceptive stimuli linked to the "microtraumatic" use of the hands which is limited only to the affected hand. Such absence is also presumably responsible for lack of node production related to enthesitic ossification at the distal phalanx level. We agree with Etherington and Spector5 about the possibility that several valid concepts relating to the protective effects of neurological lesions, either central or periph-X ray examination of the hands shows, on the left side, underdevelopment of the bones of the carpus, metacarpus, and phalanges without osteodegenerative lesions of the distal interphalangealjoints; Heberden's nodes are present on the right side. with characteristic anterior curvature of the spine ("ptosis") which disappeared completely when the patient assumed the supine position. They were asymptomatic for back pain. There was no neurological deficit or psychiatric disturbance. The computer tomography (CT) scan of the thoracolumbar spine showed diffuse atrophy of the paraspinal muscles and heterogeneity of signal with areas consistent with increased water content; however, the CT findings in this condition are difficult to interpret and there is some debate about the range normality in the elderly. Electromyography of the lumbar paraspinal and other muscles revealed a myopathic pattern. Muscle biopsy was not performed as no subject agreed to this procedure.
We propose that the term "cormoptosis" should be used for the clinical picture of painless stoop in the elderly. The word derives from the Greek word cormos (meaning body or trunk) and ptosis (meaning passive movement downward: exactly the picture seen in this disorder). The word "camptocormia" includes the Greek word campto meaning to bend forward actively, which is what is seen in military recruits who have what is essentially a psychogenic disorder. The "p" in cormoptosis as well in apoptosis should be pronounced. "Proclinorachie" has the similar meaning in Greek, as the word camptocormia.6
